MUMBAI, India, June 30 -- Intellectual Property India has published a patent application (202637024562 A) filed by Rigerna Therapeutics Co. , Ltd. on March 02, 2026, for Inhbe Gene-Targeted Double-Stranded Oligonucleotide, Conjugate, Composition And Use Thereof.
Inventors include Huang, Yuanyu; Li, Haitao; and Kong, Lina.
The application for the patent was published on June 26, 2026, under issue no. 26/2026.
Abstract: Provided are an INHBE gene-targeted double-stranded oligonucleotide, a conjugate, and a composition, which relate to the technical field of nucleic acid drugs. The double-stranded oligonucleotide comprises a sense strand and an antisense strand. The antisense strand is complementary or substantially complementary to the sense strand; the sense strand comprises a nucleotide sequence identical or substantially identical to at least 15 consecutive nucleotides in a sequence of SEQ ID NO: 309, and said substantially identical means that there is no more than three nucleotide differences between the sense strand and the at least 15 consecutive nucleotides in the sequence of SEQ ID NO: 309. The double-stranded oligonucleotide can effectively inhibit the INHBE gene and treat patients suffering from metabolic diseases or metabolic syndrome and related diseases such as diabetes, hypertension and cardiovascular diseases.
Disclaimer: Curated by HT Syndication.
